Hepatitis C News and Research

Latest Hepatitis C News and Research

ACP awarded $1,002,884 Cooperative Agreement to increase adult immunization rates in US

The American College of Physicians (ACP) was awarded a $1,002,884 Cooperative Agreement from the Centers for Disease Control and Prevention (CDC) to increase immunization rates in the United States.

16 Sep 2015

Sun Biomedical begins DMX-200 Phase II trial for treatment of chronic kidney disease

Sun Biomedical Limited today announced the first patient had been enrolled in a Phase II study of DMX-200, an innovative new treatment that combines two different drugs to treat chronic kidney disease.

15 Sep 2015

NYUCN researchers study sexual transmission of HCV among HIV-positive MSM

While sexual contact is not the most efficient means of hepatitis C (HCV) transmission, there have been several reports of outbreaks of sexually transmitted HCV in HIV-positive men who have sex with men (MSM). HCV infections are more likely to become persistent and to lead to progressive liver disease in people who are HIV-infected, even if they are receiving HIV treatment. Factors underlying these infections in HIV-positive MSM are only partially understood.

14 Sep 2015

Psychosis, hepatitis C infection are greatest risk factors for mortality in marginalized Vancouver residents

Marginalized residents of Vancouver's Downtown Eastside are dying at more than eight times the national average, and treatable conditions are the greatest risk factors for mortality, researchers at the University of British Columbia have found.

11 Sep 2015

DNDi announces successful completion of SCYX-7158 Phase I study for treatment of sleeping sickness

The Drugs for Neglected Diseases initiative (DNDi) has announced today at the 9th European Congress on Tropical Medicine and International Health in Basel, Switzerland, the successful completion of Phase I human clinical trials for SCYX-7158 (AN5568), the first oral drug candidate specifically developed from the earliest drug discovery stage to combat human African trypanosomiasis, or sleeping sickness, a deadly parasitic disease transmitted by the tsetse fly.

9 Sep 2015

DNDi unveils plans to better respond to the needs of neglected patients

After having built the world's largest drug development pipeline for the most neglected diseases, the Drugs for Neglected Diseases initiative (DNDi) has unveiled plans for a more flexible, dynamic portfolio approach, integrating various operating models to better respond to the needs of patients, notably in low- and middle-income countries. The plan also paves the way for new diseases to be taken up in DNDi's portfolio.

9 Sep 2015

HIV prevention program undergoes “real world” evaluation

A programme that provides pre-exposure prophylaxis (PrEP) to prevent HIV infection among sexually active gay men has not seen one case of HIV infection since it began in 2012, according to the first “real world” evaluation of the regimen at Kaiser Permanente San Francisco Medical Center.

4 Sep 2015

Penn researchers identify viral products that trigger immune response against RSV infection

Almost all human beings are exposed to the respiratory syncytial virus, or RSV, before their second birthdays. For most, the symptoms mimic those of the common cold: runny nose, coughing, sneezing, fever.

4 Sep 2015

HBV DNA levels guide antiviral treatment in chemotherapy setting

Pretreatment levels of hepatitis B virus DNA could inform the withdrawal of pre-emptive antiviral therapy in chronic HBV patients undergoing cytotoxic chemotherapy for cancer, indicate research findings published in Digestive Diseases and Sciences.

3 Sep 2015

Countrywide variations in chronic HBV burden revealed

A systematic review of the worldwide prevalence of chronic hepatitis B virus infection finds wide variation between countries.

3 Sep 2015

Risk score predicts ACLF risk in chronic HBV patients

A risk score incorporating routinely collected clinical information can identify patients with chronic hepatitis B virus infection at high risk of developing acute-on-chronic liver failure following severe acute exacerbation, research suggests.

3 Sep 2015

Inhalation exposure to PM2.5 pollution triggers liver fibrosis

A research team led by Kezhong Zhang, Ph.D., at the Wayne State University School of Medicine's Center for Molecular Medicine and Genetics, has discovered that exposure to air pollution has a direct adverse health effect on the liver and causes liver fibrosis, an illness associated with metabolic disease and liver cancer.

3 Sep 2015

World leaders meet at World Hepatitis Summit to discuss prevention strategies for viral hepatitis

Today marks the start of the first-ever World Hepatitis Summit hosted in Glasgow, Scotland, at the Scottish Exhibition and Conference Centre.

3 Sep 2015

Ascletis completes US$35 million (RMB 220 million) financing

Ascletis announced today the completion of a US$35 million (RMB 220 million) financing. The investment was led by C-Bridge Capital, joined by Tasly Pharmaceutical and Singapore-based Pavilion Capital. The valuation of the Company before financing was US$300 million.

2 Sep 2015

World Hepatitis Summit highlights need to develop national programmes that can eliminate viral hepatitis

Participants at the first-ever World Hepatitis Summit will urge countries to develop national programmes that can ultimately eliminate viral hepatitis as a problem of public health concern.

2 Sep 2015

ECHO Autism program to be expanded to additional 10 sites

Dr. Kristin Sohl, a pediatrician at the University of Missouri Thompson Center for Autism and Neurodevelopmental Disorders, will expand the growing ECHO Autism program, which launched in March, to an additional 10 sites.

2 Sep 2015

Nektar receives $40 million cash payment from first commercial sale of MOVENTIG (naloxegol)

Nektar Therapeutics announced today that it has received a $40 million cash payment under a license agreement with AstraZeneca. The payment was triggered by the first commercial sale of MOVENTIG (naloxegol) in Germany.

1 Sep 2015

Regen BioPharma develops novel means of delivering RGBP-248 gene silencing nucleic acid to liver tumors

Regen BioPharma, Inc. announced today development of a novel means of delivering its patented (US Patent 8,263,571) gene silencing nucleic acid, RGBP-248, to liver tumors utilizing a clinically approved formulation as delivery system. The product in development overcomes previous hurdles with gene silencing therapeutics in which the gene silencing drug had to be delivered throughout the whole body.

31 Aug 2015

Ascletis receives TFDA approval to begin Phase II trial of interferon-free HCV regimen

Ascletis today announced it received the approval from the Taiwan Food and Drug Administration (TFDA) to start phase II clinical trial for its all-oral interferon (IFN)-free regimen to treat chronic hepatitis C (CHC).

31 Aug 2015

Vaccine exemption levels low, vaccination rates high in U.S.

Vaccine exemption levels for kindergarteners are low for most states and infant vaccination rates are high nationally, according to data from two reports published in this week's Morbidity and Mortality Weekly Report.

28 Aug 2015

Hepatitis C News and Research

Latest Hepatitis C News and Research

ACP awarded $1,002,884 Cooperative Agreement to increase adult immunization rates in US

Sun Biomedical begins DMX-200 Phase II trial for treatment of chronic kidney disease

NYUCN researchers study sexual transmission of HCV among HIV-positive MSM

Psychosis, hepatitis C infection are greatest risk factors for mortality in marginalized Vancouver residents

DNDi announces successful completion of SCYX-7158 Phase I study for treatment of sleeping sickness

DNDi unveils plans to better respond to the needs of neglected patients

HIV prevention program undergoes “real world” evaluation

Penn researchers identify viral products that trigger immune response against RSV infection

HBV DNA levels guide antiviral treatment in chemotherapy setting

Countrywide variations in chronic HBV burden revealed

Risk score predicts ACLF risk in chronic HBV patients

Inhalation exposure to PM2.5 pollution triggers liver fibrosis

World leaders meet at World Hepatitis Summit to discuss prevention strategies for viral hepatitis

Ascletis completes US$35 million (RMB 220 million) financing

World Hepatitis Summit highlights need to develop national programmes that can eliminate viral hepatitis

ECHO Autism program to be expanded to additional 10 sites

Nektar receives $40 million cash payment from first commercial sale of MOVENTIG (naloxegol)

Regen BioPharma develops novel means of delivering RGBP-248 gene silencing nucleic acid to liver tumors

Ascletis receives TFDA approval to begin Phase II trial of interferon-free HCV regimen

Vaccine exemption levels low, vaccination rates high in U.S.

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Hepatitis C News and Research

Latest Hepatitis C News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in